- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ensuring PNH Treatment Access and Adherence to Therapies
Barriers to care and treatment adherence for patients diagnosed with PNH is discussed.
EP: 1.PNH Overview and Pathophysiology
EP: 2.Intravascular and Extravascular Hemolysis MoA in PNH
EP: 3.Utilizing Health Information Technology to Bridge Gaps in PNH Treatment Programming
EP: 4.Key Treatment Considerations for Patients Diagnosed With PNH
EP: 5.Complement System Role in PNH Treatment Approach
EP: 6.Eculizumab Impact on PNH Treatment Landscape and Unmet Needs in PNH Management
EP: 7.Efficacy End Points For PNH Treatment
EP: 8.Efficacy and Safety Trials Results of Complement Inhibitors
EP: 9.Treatment Adherence and Cost Considerations Surrounding Various Routes of PNH Treatment Administration
EP: 10.Investigational Therapies Paving New PNH Treatment Pathways
EP: 11.Key Financial Factors Associated With Typical PNH Treatment Journey
EP: 12.Navigating Transfusion Requirements in PNH Treatment
EP: 13.Considerations for Managing PNH Treatment Complications
EP: 14.Infection Risk Management Counseling For Patients Receiving Treatment for PNH
EP: 15.Ensuring PNH Treatment Access and Adherence to Therapies
EP: 16.Financial Considerations Influencing Treatment Strategies in PNH Treatment Pathway
Video content above is prompted by the following questions:
- What strategies can effectively ensure seamless access to therapies (eg, partnering with specialized pharmacies for dispensing)?
- When considering treatment options, how do factors related to supporting and enhancing adherence influence your choice of therapy? Could you discuss the opportunities and approaches you leverage to promote optimal treatment adherence in this patient population?
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines
July 31st 2025On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory multiple myeloma (MM), and the most recent update to the National Comprehensive Cancer Network guidelines for MM has added the BCMA-targeted bispecific antibody as a preferred treatment option.
Read More
Obe-Cel Outcomes by Age; Brexu-Cel Expansion as a Predictor of Relapse-Free Survival in R/R ALL
July 30th 2025Obecabtagene autoleucel (obe-cel) is shown to be effective and safe for older adults with relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (ALL), while brexucabtagene autoleucel's (brexu-cel) expansion predicts durable remission.
Read More
